Drug Trial Radar · NCT00802672
Safety and Equivalence of a Generic Ciclopirox Olamine Cream Compared to the Reference Ciclopirox Cream 0.77% for the Treatment of Tinea Pedis
Last checked: Nov 20, 2026Latest source record: Oct 13, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
561
Actual
Start
Dec 2003
Primary completion
May 2004
Study completion May 2004
Sponsor
- Lead sponsor
- Padagis LLCIndustry
- Sponsor type
- Industry
- First posted
- Dec 5, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 10 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objectives of this study were to demonstrate comparable safety and efficacy of Ciclopirox Olamine Cream (Test Product) and Ciclopirox Cream 0.77% (Reference Product) in the treatment of subjects with tinea pedis, and to show the superiority of the active treatments over that of the vehicle.
Conditions
- Tinea Pedis
Interventions
Ciclopirox Olamine CreamDrug
topical cream
Loprox Cream 0.77%Drug
topical cream
PlaceboDrug
topical cream
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Subjects in Each Treatment Group With Therapeutic SuccessTime frame: 6 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.